230 related articles for article (PubMed ID: 38150881)
1. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
[TBL] [Abstract][Full Text] [Related]
2. A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa.
Jepsen R; Edwards C; Flora A; Kozera E; Frew JW
J Am Acad Dermatol; 2023 Oct; 89(4):694-702. PubMed ID: 37307994
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
Kirby JS; Okun MM; Alavi A; Bechara FG; Zouboulis CC; Brown K; Santos LL; Wang A; Bibeau KB; Kimball AB; Porter ML
J Am Acad Dermatol; 2024 Mar; 90(3):521-529. PubMed ID: 37871805
[TBL] [Abstract][Full Text] [Related]
4. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review.
Guermazi D; Shah A; Yumeen S; Saliba E
Arch Dermatol Res; 2024 May; 316(6):259. PubMed ID: 38795234
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
Alavi A; Hamzavi I; Brown K; Santos LL; Zhu Z; Liu H; Howell MD; Kirby JS
Br J Dermatol; 2022 May; 186(5):803-813. PubMed ID: 34978076
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
8. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
9. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
[TBL] [Abstract][Full Text] [Related]
10. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies.
Liu H; Santos LL; Smith SH
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108348
[TBL] [Abstract][Full Text] [Related]
12. Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature.
Martora F; Scalvenzi M; Ruggiero A; Potestio L; Battista T; Megna M
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109759
[No Abstract] [Full Text] [Related]
13. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.
Agarwal A; Diaz A; Al-Dehneem R; Pineda RM; Khattri S
J Drugs Dermatol; 2023 Dec; 22(12):1183-1190. PubMed ID: 38051858
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Alam MS; Papp KA; Desjardins O; Jean C
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2431-2439. PubMed ID: 34378812
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
16. Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
Dhir B; Meena SK; Sardana K; Sharath S
Pediatr Dermatol; 2024; 41(1):139-140. PubMed ID: 37495552
[TBL] [Abstract][Full Text] [Related]
17. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
18. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H; Jia H; Xia T; Zhang D
Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
